Clinical Trials Logo

Cutaneous Melanoma, Stage III clinical trials

View clinical trials related to Cutaneous Melanoma, Stage III.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03655756 Completed - Clinical trials for Cutaneous Melanoma, Stage IV

pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma

Start date: November 5, 2018
Phase: Early Phase 1
Study type: Interventional

Six patients will receive IFx-Hu2.0 on an outpatient basis at a single time point in a single lesion, two lesions, or three lesions, as a monotherapy (a maximum of three lesions could be injected). These patients will be assessed for any immediate adverse reactions and at Week 4 (Day 28+/-7 business days for any delayed adverse events.

NCT ID: NCT03541148 Completed - Clinical trials for Cutaneous Melanoma, Stage III

Evaluation of Oncoxin-Viusid® in Cutaneous Melanoma

Start date: September 16, 2014
Phase: Phase 2
Study type: Interventional

Malignant melanoma, responsible for 75% of deaths from skin cancer. Current therapeutic options have poor response, many adverse events and high costs. For this reason, a study with nutritional supplement Oncoxin-Viusid was carried out. According to previous studies, it has an antitumor, immunomodulatory effect and to potentiate the antiproliferative effect of standard chemotherapeutic agents in different locations and stages of cancer.